Friedreich Ataxia iPSC-derived microglia display an interferon-responsive, antigen-presenting, and inflammasome-associated state with lysosomal biology and extracellular matrix abnormalities

Friedreich ataxia is a devastating genetic condition that slowly robs people of their ability to move and coordinate their bodies. It stems from a flaw in a single gene that prevents the body from making enough of a protein called frataxin. This protein is essential for the tiny power plants inside our cells, known as mitochondria, to function correctly. Without it, these power plants struggle, leading to a cascade of cellular failures that eventually destroy specific nerve cells responsible for balance and movement. For decades, the medical focus has been almost entirely on these dying nerve cells, viewing them as the primary victims of the disease. However, the nervous system is a complex community, and the cells that support and protect neurons are just as vital. Among these supporters are microglia, the brain's resident immune cells. Their job is to maintain order, clear away debris, and respond to injury. Recent clues suggest that in Friedreich ataxia, these guardians might not just be reacting to the damage, but might actually be part of the problem, turning against the very cells they are meant to protect.

A team of researchers at McGill University set out to understand exactly how this happens. They wanted to know if the lack of frataxin alone was enough to change the behavior of microglia, even before any nerve cells began to die. To find the answer, they turned to a powerful tool that allows scientists to study human cells in a dish: induced pluripotent stem cells. These are cells that can be coaxed into becoming any type of tissue in the body. The researchers took skin cells from patients with Friedreich ataxia and reprogrammed them into stem cells. They then guided these stem cells to become microglia. Crucially, they also created a control group by editing the genes of these same cells to remove the disease-causing mutation, creating a perfect genetic match that lacked the flaw. This allowed them to compare the two groups side by side, ensuring that any differences they found were due solely to the missing frataxin protein and not other variables.

The researchers grew these microglia under calm, quiet conditions, without introducing any external infections or injuries that would normally trigger an immune response. They wanted to see what the cells were doing on their own. When they analyzed the genetic instructions inside the cells, they found a startling difference. The microglia from the patients were already in a state of high alert, even though they were sitting in a peaceful environment. Their genetic activity showed a clear signature of an immune system that had been switched on. Specifically, these cells were behaving as if they were fighting an infection, producing a flood of signals known as interferons, which are typically used to warn the body of viral threats. They were also displaying proteins on their surface that act like flags, a process usually reserved for presenting foreign invaders to the immune system. This suggested that the cells were not just reacting to the outside world, but were internally primed for a fight.

Digging deeper, the team discovered that this internal alarm was driven by a specific set of molecular machines called inflammasomes. These are complex structures inside cells that act as sensors for danger. When they detect trouble, they assemble into a large, multi-part machine that triggers the release of powerful inflammatory chemicals. The researchers found that the patient microglia had significantly higher levels of two specific types of these machines, known as NLRP2 and NLRP3. Furthermore, they observed that the components of these machines were actively coming together, forming large clusters that are necessary for them to work. This assembly was accompanied by an increase in the active forms of a key enzyme that cuts and releases inflammatory signals. In short, the cells had built their own weapons and were ready to fire, all without any external provocation.

The study also revealed that the internal machinery of these cells was struggling. The microglia showed signs of trouble with their lysosomes, which are the recycling centers of the cell responsible for breaking down waste and damaged parts. The researchers found that the proteins that make up these recycling centers were reduced, suggesting that the cells were having trouble cleaning up their own internal mess. This inability to clear out cellular waste is likely a major factor in keeping the immune system in a constant state of alarm. Additionally, the cells were secreting a different mix of proteins into their surroundings compared to healthy cells. They were releasing high levels of inflammatory chemicals that can damage nearby tissue, while producing less of the proteins that help cells stick to their environment and to each other. This combination of internal dysfunction and external aggression paints a picture of a cell that is both confused and dangerous.

One of the most intriguing findings was the behavior of a specific gene called MEG3. This gene, which produces a type of RNA that does not code for a protein but instead helps regulate other genes, was turned up to high levels in the patient microglia. The researchers noted that this same gene had been found to be overactive in heart muscle cells from patients with the same disease, and that turning it down in those heart cells helped them survive. This suggests that MEG3 might be a common thread linking the different ways the disease affects the body, acting as a shared mechanism that drives damage in multiple types of cells.

The implications of these findings are significant for how we think about treating Friedreich ataxia. The study demonstrates that the immune cells in the brain are not merely passive bystanders waiting for nerve cells to die; they are active participants in the disease process, driven by their own internal genetic flaws. The lack of frataxin is sufficient to turn these protective cells into agents of inflammation. This suggests that there may be a window of opportunity early in the disease, perhaps even before the nerve cells start to show signs of failure, where targeting these overactive microglia could slow down or stop the progression of the condition. By understanding the specific molecular switches that are flipped in these cells, such as the inflammasome machines or the MEG3 gene, scientists may be able to design new therapies that calm the immune system and protect the nervous system from within. The work provides a clear map of the cellular changes that occur when frataxin is missing, offering new targets for future treatments that could one day change the course of this relentless disease.